Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Monopar Therapeutics raised $100 million in a stock offering to fund research and development.
Monopar Therapeutics priced a $135 million underwritten offering of common stock and pre-funded warrants, with proceeds expected to net about $100 million after a $35 million stock repurchase from Tactic Pharma.
The company plans to use funds for research, clinical trials, manufacturing, and working capital.
The offering, managed by Morgan Stanley, Leerink Partners, and Barclays, is set to close on September 25, 2025, and is part of a shelf registration filed with the SEC.
The securities are being offered under a prospectus supplement available on the SEC’s website.
Monopar is developing treatments for Wilson disease and advanced cancers.
Forward-looking statements involve risks related to regulatory and market factors.
Monopar Therapeutics recaudó $100 millones en una oferta de acciones para financiar investigación y desarrollo.